Drug intelligence / Profile preview

wIPV-wIPV-bOPV

Development stage: Preclinical
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral

Overview

wIPV-wIPV-bOPV appears to be a polio vaccination schedule that combines two doses of inactivated poliovirus vaccine (IPV) followed by a dose of bivalent oral poliovirus vaccine (bOPV). This combination approach aims to provide both humoral immunity through IPV and mucosal immunity through OPV. IPV contains killed poliovirus that cannot cause disease but stimulates antibody production, while bOPV contains weakened live virus strains that can provide intestinal immunity but carries a small risk of vaccine-derived poliovirus.

Beyond the preview

Go deeper on wIPV-wIPV-bOPV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on wIPV-wIPV-bOPV.

Explore the full profile